| Source: |
| Type: |
| Lactate production has been linked to cancer development and progression. In normal conditions, lactate is produced in cells through a process called glycolysis, which breaks down glucose to generate energy. However, in cancer cells, this process is often upregulated, leading to increased lactate production, even in the presence of oxygen. This phenomenon is known as the Warburg effect. -Lactate is the end product of glycolysis and induces TGFβ1 upregulation and the acidic microenvironment. |
| 5277- | 3BP, | 3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model |
| - | in-vivo, | PC, | Panc02 |
| 944- | AG, | Astragalus saponins inhibit cell growth, aerobic glycolysis and attenuate the inflammatory response in a DSS-induced colitis model |
| - | vitro+vivo, | CRC, | NA |
| 3454- | ALA, | Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 6596- | Anamu, | Effect of Petiveria alliacea Extracts on Metabolism of K562 Myeloid Leukemia Cells |
| - | in-vitro, | AML, | K562 |
| 206- | Api, | Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Lung, | H2030 | - | in-vitro, | CRC, | SW480 |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 566- | ART/DHA, | 2DG, | Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
| 2323- | ART/DHA, | Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 |
| 2320- | ART/DHA, | Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis |
| - | in-vitro, | AML, | K562 | - | in-vitro, | Liver, | HepG2 |
| 2388- | Ash, | Withaferin A decreases glycolytic reprogramming in breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-453 |
| 3156- | Ash, | Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug |
| - | Review, | Var, | NA |
| 996- | Ba, | Tam, | Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α |
| 2620- | Ba, | Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review |
| - | Review, | GC, | NA |
| 2335- | BBR, | Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 940- | BBR, | Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression |
| - | vitro+vivo, | PC, | PANC1 | - | in-vivo, | PC, | MIA PaCa-2 |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2740- | BetA, | Effects and mechanisms of fatty acid metabolism-mediated glycolysis regulated by betulinic acid-loaded nanoliposomes in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 |
| 943- | BetA, | Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1261- | CAP, | Capsaicin inhibits glycolysis in esophageal squamous cell carcinoma by regulating hexokinase‑2 expression |
| - | in-vitro, | ESCC, | KYSE150 |
| 939- | Catechins, | 5-FU, | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil |
| - | vitro+vivo, | GC, | SNU620 |
| 6128- | CHr, | Chrysin: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Potential |
| - | Review, | Nor, | NA | - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2782- | CHr, | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 1143- | CHr, | Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2 |
| - | in-vitro, | HCC, | HepG2 | - | in-vivo, | NA, | NA | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | HUH7 |
| 1585- | Citrate, | Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Nor, | HEK293 |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 2308- | CUR, | Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 466- | CUR, | Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1 |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HuT78 |
| 6685- | DAP, | Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1 |
| - | in-vitro, | Lung, | H1975 |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 6682- | DCA, | QC, | Dichloroacetate and Quercetin Prevent Cell Proliferation, Induce Cell Death and Slow Tumor Growth in a Mouse Model of HPV-Positive Head and Neck Cancer |
| - | in-vivo, | HNSCC, | MEER |
| 6681- | DCA, | Dichloroacetate (DCA) in Cancer Care |
| - | Trial, | HNSCC, | NA |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 5195- | DCA, | Rad, | Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | EMT6 |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1882- | DCA, | Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer |
| - | Analysis, | NA, | NA |
| 1869- | DCA, | Dichloroacetate induces autophagy in colorectal cancer cells and tumours |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HT-29 |
| 1866- | DCA, | MET, | BTZ, | Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner |
| - | in-vivo, | NA, | NA |
| 6705- | DFC, | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases |
| - | Review, | Var, | NA |
| 6700- | DFC, | Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6706- | DFC, | MET, | Frontiers | Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells |
| - | in-vitro, | AML, | U937 |
| 6708- | DFC, | Repurposing Drugs as Expanding Cancer Treatment Palette: Diclofenac |
| 6696- | DFC, | MET, | Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma |
| - | in-vitro, | GBM, | GBM |
| 6688- | DFC, | New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells |
| - | in-vivo, | lymphoma, | U937 |
| 6694- | DFC, | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| - | Review, | Var, | NA |
| 6695- | DFC, | Inhibition of lactate dehydrogenase A by diclofenac sodium induces apoptosis in HeLa cells through activation of AMPK |
| - | in-vitro, | Cerv, | HeLa |
| 951- | DHA, | Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 1861- | dietFMD, | Chemo, | Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models |
| - | in-vitro, | Colon, | CT26 | - | in-vivo, | NA, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:739 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid